Catheter Ablation Versus Sham Procedure for Symptomatic Atrial Fibrillation: The PVI-SHAM-AF Trial

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  The Lancet https://doi.org/10.1016/S0140-6736(26)01558-8
Dr. Rolf Wachter et al.

Points

University of Leipzig Medical Center and Charité Berlin investigators conducted a double blind trial comparing catheter ablation against a sham procedure in two hundred sixty two symptomatic atrial fibrillation patients.
Both treatment cohorts exhibited substantial six month improvements in disease specific quality of life scores, showing no statistically significant difference between the active ablation and placebo groups.
Patients undergoing active catheter ablation achieved significantly higher rates of freedom from atrial fibrillation recurrence after six months when compared to those in the sham intervention arm.
Safety outcomes revealed low complication rates across both study arms, with vascular access issues occurring in three ablation patients and two sham control participants throughout trial follow up.
Trial researchers concluded that quality of life benefits following atrial fibrillation ablation stem primarily from placebo mechanisms or medical care optimization rather than direct invasive electrophysiological disruption.

Summary

This multicenter, double-blind, sham-controlled trial evaluated the efficacy of catheter ablation compared with a sham procedure for improving disease-specific quality of life in patients with symptomatic paroxysmal or persistent atrial fibrillation (AF). Led by Rolf Wachter and Nikolaos Dagres across nine sites in Germany and Poland, the PVI-SHAM-AF study randomized 262 patients in a 2:1 ratio to receive catheter ablation or a sham intervention involving conscious sedation and vascular access without catheter placement. The primary endpoint was the change from baseline to six months in the Atrial Fibrillation Effect on Quality of Life (AFEQT) summary score.

At six months follow-up, AFEQT summary scores improved in both treatment arms, increasing from 61.3 to 81.1 in the ablation group and from 59.2 to 74.9 in the sham group, yielding no statistically significant difference between interventions (p = 0.36). However, freedom from AF recurrence at six months was significantly higher in the catheter ablation cohort compared to the sham cohort (73% vs. 52%). Procedure-related serious adverse events occurred in six patients receiving ablation and four patients receiving sham, with five total vascular access complications (three ablation, two sham).

Screening logs indicated that 937 of 1,199 invited patients declined participation, introducing potential selection bias toward individuals with lower symptom burdens or differing treatment expectations. The authors concluded that while catheter ablation effectively enhances rhythm control and suppresses AF recurrence, observed quality-of-life improvements are largely driven by placebo responses or non-procedural care factors rather than ablation itself.

Link to the article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01558-8/fulltext

References

Wachter, R., Haag, P., Uhe, T., Bacak, M., Petroff, D., Forkmann, M., Eckardt, L., Gaspar, T., Dinov, B., Neef, M., Bode, K., Seewöster, T., Nedios, S., Hilbert, S., Lerche, M., Lindemann, F., Spies, C., Beimel, S., Paiva, B. T. C., … Kowalczyk, J. (2026). Catheter ablation for symptomatic atrial fibrillation (Pvi-sham-af): A randomised, double-blind, sham-controlled, multicentre trial. The Lancet, S0140673626015588. https://doi.org/10.1016/S0140-6736(26)01558-8